来源：问董秘 您好，感谢您的关注与建议。公司如有应审议披露事项，会及时履行审议程序与信息披露义务，谢谢。 查看更多董秘问答>> 投资者提问： 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 公司应对出海和全球化战略，可否考虑在香港市场发行股份也上市呢？ 董秘回答(鱼跃医疗SZ002223)： ...

Group 1 - The medical sector experienced volatility, with the largest medical ETF in A-shares (512170) dropping over 2% in the afternoon, with real-time transactions exceeding 490 million yuan [1] - The ETF's latest scale is 25.73 billion yuan, ranking first among similar ETFs [1] - Notable declines were observed in constituent stocks, with Sanbo Brain Science falling over 6%, and other companies like Yingke Medical and Nanwei Medical dropping more than 4% [1] Group 2 - Ping An Securities indicated that the bidding environment for medical devices will remain favorable in 2025, with strong demand for ultrasound, CT, and MRI equipment driven by policy incentives [3] - The pharmaceutical and biotechnology sectors are currently affected by policy disruptions, but the long-term industry trend remains unchanged, with Chinese innovative drug companies gaining global competitiveness [3] - The medical ETF (512170) passively tracks the CSI Medical Index, with its top ten weighted stocks including WuXi AppTec, Mindray Medical, and others [3]

Core Viewpoint - Yuyue Medical's stock price has shown fluctuations, with a recent decline of 2.05% on October 17, 2023, reflecting a total market capitalization of 37.38 billion yuan and a year-to-date increase of 3.90% [1] Financial Performance - For the first half of 2025, Yuyue Medical reported a revenue of 4.659 billion yuan, representing a year-on-year growth of 8.16%, and a net profit attributable to shareholders of 1.203 billion yuan, which is a 7.37% increase compared to the previous year [2] Shareholder Information - As of September 30, 2023, the number of shareholders for Yuyue Medical stood at 50,000, with an average of 18,803 circulating shares per person, indicating no change from the previous period [2] - The company has distributed a total of 4.415 billion yuan in dividends since its A-share listing, with 2.402 billion yuan distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, the top circulating shareholders include Huabao Zhongzheng Medical ETF, holding 20.005 million shares, an increase of 347,900 shares from the previous period, while Hong Kong Central Clearing Limited reduced its holdings by 6.963 million shares [3]

Core Points - The Bioeconomy Index (970038) closed at 2319.65 points, up 1.32%, with a trading volume of 23.929 billion yuan and a turnover rate of 1.64% [1] - Among the index constituents, 39 stocks rose while 11 fell, with Boteng Co., Ltd. leading the gainers at 6.85% and Dabo Medical leading the decliners at 2.94% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 230.50, and a market cap of 279.468 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 127.16, and a market cap of 51.873 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 31.35, and a market cap of 55.746 billion yuan [1] - Other notable constituents include Taige Pharmaceutical, Deep Technology, and Muyuan Foods, each with varying weights and market caps [1] Capital Flow Analysis - The Bioeconomy Index constituents experienced a net inflow of 265 million yuan from institutional investors, while retail investors saw a net outflow of 72.932 million yuan [3] - Key stocks with significant capital flow include: - Mindray Medical with a net inflow of 79.5868 million yuan from institutional investors [3] - Xintai (002294) with a net inflow of 66.974 million yuan, but a net outflow of 87.6434 million yuan from retail investors [3] - Changchun High-tech also saw a net inflow of 66.9424 million yuan from institutional investors, with a notable outflow from retail investors [3]

Core Viewpoint - Yuyue Medical's stock has shown a modest increase of 2.01% on October 14, with a current price of 38.51 CNY per share and a total market capitalization of 38.605 billion CNY [1] Financial Performance - For the first half of 2025, Yuyue Medical reported a revenue of 4.659 billion CNY, representing a year-on-year growth of 8.16%, and a net profit attributable to shareholders of 1.203 billion CNY, which is a 7.37% increase compared to the previous year [2] Shareholder Information - As of September 30, Yuyue Medical had 50,000 shareholders, with an average of 18,803 circulating shares per person, showing no change from the previous period [2] - The company has distributed a total of 4.415 billion CNY in dividends since its A-share listing, with 2.402 billion CNY distributed in the last three years [3] Stock Trading Activity - On October 14, the net inflow of main funds was 11.4959 million CNY, with significant buying and selling activity noted [1] - The stock has experienced a year-to-date increase of 7.30%, with a slight decline of 3.24% over the past 20 days [1] Business Segmentation - Yuyue Medical's main business segments include respiratory treatment solutions (35.93%), clinical instruments and rehabilitation solutions (24.35%), home health monitoring solutions (21.77%), blood glucose management and POCT solutions (14.48%), and emergency solutions (2.92%) [1]

Core Insights - Jiangsu Yuyue Medical Equipment Co., Ltd. has been recognized as a respected enterprise for the 2024-2025 period by Economic Observer, highlighting its excellent performance in quality operations, innovation breakthroughs, and social contributions [1] Group 1 - The company has shown outstanding performance in various indicators, including quality operations, innovation breakthroughs, and social contributions [1] - The company has achieved positive growth in R&D expenses for three consecutive years, according to the comprehensive value assessment system for listed companies by Economic Observer [1]

Core Viewpoint - Yuyue Medical's Q2 revenue and net profit attributable to shareholders met expectations, with net profit slightly exceeding expectations due to increased government subsidies in non-recurring gains during the first half of the year [1] Group 1: Financial Performance - Q2 revenue and net profit attributable to shareholders were in line with expectations, while net profit slightly exceeded expectations [1] - Significant growth observed in home respiratory devices, continuous glucose monitoring (CGM), and emergency business sectors [1] - Steady growth in home health testing business [1] Group 2: Future Outlook - Domestic business is expected to maintain steady growth due to the recovery of consumer demand and continuous market share increase [1] - Overseas business is anticipated to see accelerated growth [1] - The company is advancing its internationalization, smart technology, and wearable strategy [1] Group 3: Product Development and Strategy - Continuous iteration and diversification of new products are underway [1] - AI empowerment is expected to help create a platform ecosystem for home medical devices [1] - The company aims to further solidify its position as a leading platform-type enterprise in home medical devices [1]

Core Insights - The rehabilitation equipment industry in China is rapidly growing, with the market size expected to reach approximately 714.6 billion yuan in 2024, an increase of 98.9 billion yuan from 2023 [1][6] - The largest market share within the rehabilitation equipment sector is held by rehabilitation therapy devices at 15%, followed by rehabilitation training devices at 4%, and rehabilitation assessment devices at 1% [6] - The market is projected to grow further, reaching an estimated 815 billion yuan by 2025, driven by an aging population and increasing demand for rehabilitation services [1][6] Industry Definition and Classification - Rehabilitation medical devices are defined as equipment used for the prevention, assessment, treatment, training, or compensation of functional disabilities [3] - The main categories of rehabilitation medical devices include rehabilitation aids, rehabilitation therapy devices, rehabilitation training devices, rehabilitation assessment devices, and other rehabilitation equipment [3] Current Development Status - The rehabilitation equipment market in China is predominantly composed of domestic brands, which account for 97.9% of the market, while imported brands make up about 3% [6] - The industry has seen significant expansion in both market size and application areas due to rapid economic development [6] Industry Chain - The upstream of the rehabilitation equipment industry includes raw materials and software systems, while the midstream involves the manufacturing of rehabilitation devices [8] - The downstream applications primarily serve hospitals, community rehabilitation centers, nursing homes, and other medical institutions catering to populations with functional disabilities [8] Market Environment and Policies - The Chinese government has shown strong support for the rehabilitation equipment industry through various policies aimed at promoting its development, such as the "14th Five-Year" National Health Plan and guidelines for enhancing the welfare of the elderly [11] Competitive Landscape - Major companies in the rehabilitation medical device sector include Yuyue Medical, Kefu Medical, and Xiangyu Medical, with Yuyue Medical leading the market in terms of capital and revenue [12] - The industry exhibits a tiered competitive structure, with leading companies in the first tier and several others in subsequent tiers [12] Future Trends - The rehabilitation equipment industry is expected to experience significant growth opportunities, particularly in home settings, driven by an aging population and increasing chronic disease prevalence [13] - The industry is anticipated to evolve towards high-quality development, supported by technological advancements and favorable government policies [13]

Core Viewpoint - The company is integrating cutting-edge technologies like artificial intelligence into the development of its Continuous Glucose Monitoring (CGM) products, focusing on wearable medical devices for health management [2] Group 1: Product Development - The company is actively engaged in the research and development of AI-powered wearable medical devices [2] - There is an emphasis on the professional positioning of wearable products in the health sector, aiming to create products with brand characteristics and differentiated competitiveness [2] Group 2: Ecosystem Integration - The company is upgrading the Fish Leap AIAgent application to integrate with the existing "Fish Leap Health Manager" platform [2] - This integration aims to better connect users with current and future products, creating a comprehensive health management ecosystem [2]

Core Viewpoint - Yuyue Medical is accelerating its globalization strategy, with significant actions taken in September 2023, including the establishment of a subsidiary in Indonesia and participation in major medical exhibitions across nine countries, highlighting its commitment to expanding its international presence [1][2]. Group 1: Financial Performance - In the first half of 2023, Yuyue Medical reported a revenue of 4.659 billion yuan, representing a year-on-year growth of 8.16%, with overseas business revenue reaching 607 million yuan, up 26.63%, accounting for 13.03% of total revenue [1]. Group 2: Market Expansion - The establishment of the Indonesian subsidiary marks a strategic move following success in the Thai market, targeting the Southeast Asian region where approximately 90% of medical devices are imported, and the market is projected to grow at a compound annual growth rate of 10.8% from 2021 to 2026 [2]. - Yuyue Medical aims to strengthen collaboration with medical institutions, build distribution networks, and enhance after-sales service in Indonesia, leveraging its experience from the Thai market [2]. Group 3: Product Innovation and Strategy - The company is focusing on three core directions: globalization, digitalization, and wearability, with over 30 innovative products launched, including IoT-enabled devices and AI health management solutions [2]. - Yuyue Medical plans to establish branches in Europe, South America, and the Middle East, and is set to create its first shared service center in the Netherlands to improve global operational efficiency [3]. Group 4: Industry Outlook - The global medical device market is expected to reach $899.2 billion by 2030, while the home healthcare device market is projected to exceed $80.37 billion by 2033, indicating significant growth opportunities for Yuyue Medical [3].